Explore the effects of amobarbital on myocardial protection and prognosis in patients undergoing cardiac surgery with cardiopulmonary bypass, investigate the new usage of old drugs, and provide reliable clinical scientific basis for its potential value in better clinical treatment.

Start Date01 Feb 2025

Sponsor / Collaborator-

NCT06385756

/ Not yet recruitingPhase 4IIT

Effect of Amobarbital Sodium Combined With Low-dose Propofol on Hemodynamics During Induction and Perioperative Adverse Reactions in Gynecological Laparoscopic Surgery

At present, there are limited data on perioperative efficacy of barbiturates at home and abroad. The purpose of this clinical trial is to observe the effects of amobarbital sodium combined with low-dose propofol on hemodynamics during induction and perioperative adverse reactions in gynecological laparoscopic surgery patients, and to provide a more reasonable, safe and comfortable anesthesia program for female patients who undergoing laparoscopic surgery.
The main questions it aims to answer are:
* whether the combination of the two results on more stable hemodynamics during induction in gynecological laparoscopic surgery patients;
* whether the incidence of perioperative oxidative stress and inflammation and postoperative nausea and vomiting（ponv） improved after the use of the two combinations of anesthesia induction.
Participants will:
* Induction of anesthesia with the experimental drug or placebo；
* 5 ml of venous blood was retained before, after, and 1 day after surgery for follow-up determination of serum associated factor levels；
* To record their vital signs at any point during the anaesthetic process; Serum serological indexes related to oxidative stress and inflammation were determined. The agitation during the recovery period was recorded. The incidence and severity of ponv were recorded at 2h, 2-6h, and 6-24h postoperatively, and the use of palonosetron was also recorded.

Start Date01 Jun 2024

Sponsor / Collaborator-

NCT04589611

/ CompletedPhase 1/2IIT

Translating Metabolic Responses to Mechanical Insult Into Early Interventions to Prevent PTOA

This is a small-scale proof-of concept clinical trial of amobarbital as a treatment to prevent post-traumatic osteoarthritis in fractured ankle joints. The study is a double blind, prospective, randomized, placebo-controlled, stepwise trial. Amobarbital will be delivered to ankle joints in solution with hyaluronic acid (HA) as a vehicle. Amobarbital/HA injections (active dose) will be compared to HA alone (placebo dose). Our primary goal is to confirm safety, but we will also assess whether treatment improves chondrocyte viability and decreases synovial inflammation. The intervention that will be utilized has proven to be effective using vitro and in vivo models. The study team will assess safety and begin to evaluate efficacy of amobarbital/Gel-One in patients having sustained tibial pilon fractures. The study team will use advanced imaging-based methods we have developed to characterize how joints subjected to varying levels of fracture severity and residual elevated contact stress respond in treated and control groups.

Start Date20 Jul 2022

Sponsor / Collaborator

University of Iowa

[+1]

100 Clinical Results associated with Amobarbital sodium

100 Translational Medicine associated with Amobarbital sodium

100 Patents (Medical) associated with Amobarbital sodium

2,837

Literatures (Medical) associated with Amobarbital sodium

01 Dec 2025·Spine Journal

Targeting oxidative stress with amobarbital to prevent intervertebral disc degeneration: part II. Rabbit disc herniation model

Article

Author: Salem, Aliasger K ; Naguib, Youssef W ; Petersen, Emily B ; Seol, Dongrim ; Turner, Jordon D ; Marks, Jaison ; Fredericks, Douglas C ; Coleman, Mitchell C ; Ganesh, Venkateswaran ; Martin, James A ; Lim, Tae-Hong

BACKGROUND:

Evidence that oxidative stress contributes to the progression of post-traumatic intervertebral disc degeneration suggests targeting oxidant metabolism in disc cells as a strategy to mitigate degeneration in injured discs. We previously identified amobarbital, a drug that suppresses mitochondrial activity in a cell culture model with the chemical induction of oxidative stress, as a promising candidate for this purpose.

PURPOSE:

The objective of this study was to investigate the preventive effects of amobarbital on the progression of disc degeneration using a rabbit disc herniation model.

STUDY DESIGN/SETTING:

The effects of amobarbital on the prevention of disc degeneration were evaluated in both ex vivo and in vivo herniated discs.

METHODS:

Spine motion segments or animals were randomly assigned for intact control, vehicle control (hydrogel only), and amobarbital. Disc herniation was initiated by puncturing the annulus fibrosus with a needle, and amobarbital was delivered to the nucleus pulposus (NP) in a Pluronic F-127/hyaluronic acid hydrogel. A modified histological classification was applied to evaluate for degenerative cellular and matrix changes in both the annulus fibrosus and NP. Additionally, immunohistochemical staining for apoptosis and oxidative stress response, and radiography for disc height index were examined in the ex vivo and in vivo models, respectively.

RESULTS:

Amobarbital injection allowed uniform distribution in the whole NP and showed sustained release for 3 to 4 days. In an organ culture model, amobarbital treatment after a discal injury prohibited morphologic changes of notochordal cells, structural changes of extracellular matrix, endplate chondrocyte migration, and cell apoptosis compared with the vehicle control. Similarly, the preventive effects of amobarbital on disc degeneration were confirmed in an animal study, especially at 2 weeks, with maintained disc height.

CONCLUSIONS:

In summary, amobarbital injection loaded in F127/hyaluronic acid hydrogel reduced cellular and structural degenerative changes against herniated discal injuries. Therefore, amobarbital has great potential for treating degenerative disc degeneration.

CLINICAL SIGNIFICANCE:

Amobarbital encapsulated in hydrogel in this model allowed for effective local delivery into the NP and sustained release of amobarbital, which is promising for potential clinical application. Delivering amobarbital in NP cells may be a therapeutic option to retard intervertebral disc degeneration.

01 Jun 2025·FOOD CHEMISTRY

High-throughput screening of new psychoactive substances and related compounds in food by UHPLC-Q/Orbitrap

Article

Author: Huang, Xia ; Wan, Yuping ; Shi, Peiyu ; Wu, Wenlin ; Xiao, Quanwei ; Liu, Shiyao ; Guo, Tianrong ; Chen, Xiaoqi ; Zhang, Min ; Xia, Bing ; Zhou, Yan

Currently, there is concern about food products to which new psychoactive substances (NPS) have been added illegally. However, rapid, high-sensitivity, and high-throughput screening methods for such harmful substances have not been reported yet. In this study, a high-throughput non-targeted screening strategy was developed based on UHPLC-Q/Orbitrap. First, optimized pretreatment methods for typical high-risk matrices were established. Second, an accurate, efficient, and scalable high resolution mass spectrometry database containing 206 NPS and related compounds was constructed. The fragmentation pathways of three different types of fentanyl-related compounds were then systematically investigated to enhance compound identification. Additionally, a non-targeted screening strategy was developed using warning ions derived from 24 fentanyl-related compounds, streamlining the identification of NPS. This strategy was applied to 100 food samples with possible illegal additives and demonstrated its effectiveness. In summary, this study provides robust technical support for regulatory authorities in combating the illegal addition of food products.

01 Nov 2024·JOURNAL OF FORENSIC SCIENCES

High‐performance liquid chromatography coupled to Orbitrap mass spectrometry for screening of common new psychoactive substances and other drugs in biological samples

Article

Author: Nie, Manqing ; Zhao, Xuan ; Zou, Xiaoli ; Zhang, Tianai ; Wang, Xuan ; Luo, Chunying ; Wang, Lian

Abstract:

The complexity of the drug market and the constant updating of drugs have been challenging issues for drug regulatory authorities. With the emergence of new psychoactive substances (NPS) and the nonmedical use of prescription drugs, forensic and toxicology laboratories have had to adopt new drug screening methods and advanced instrumentation. Using high‐performance liquid chromatography coupled with Orbitrap mass spectrometry, we developed a screening method for common NPS and other drugs. Two milliliters of mixed solvent of n‐hexane and ethyl acetate (1:1, v:v) were added to 500 μL of blood or urine sample for liquid–liquid extraction, and methanol extraction was used for hair samples. The developed method was applied to 3897 samples (including 332 blood samples, 885 urine samples, and 2680 hair samples) taken from drug addicts in a province of China during 2019–2021. For urine and blood samples, the limits of detection (LODs) ranged from 1.68 pg/mL to 10.7 ng/mL. For hair samples, the LODs ranged from 3.30 × 10−5 to 4.21 × 10−3 ng/mg. The matrix effects of urine, blood, and hair samples were in the range of 47.6%–121%, 39.8%–139%, and 6.35%–118%, respectively. And the intra‐day precision was 3.5%–6.0% and the inter‐day precision was 4.18%–9.90%. Analysis of the actual samples showed an overall positive detection rate of 58.9%, with 5.32% of the samples indicating the use of multiple drugs.

News (Medical) associated with Amobarbital sodium

30 Jan 2023

·www.businesswire.com

Sleep Disorder Treatment Drugs Markets in China 2023: Demand to Grow by 5% Annually Through 2032 - ResearchAndMarkets.com

DUBLIN--( BUSINESS WIRE )--The "Sleep Disorder Treatment Drugs Markets in China" report has been added to ResearchAndMarkets.com's offering. China's demand for Sleep Disorder Treatment Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & export, consumer consumption and capital investment for over two decades. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2012, 2017 and 2022) and long-term forecasts through 2027 and 2032 are presented. Major producers in China are profiled. The primary and secondary research is done in China in order to access up-to-date government regulations, market information and industry data. Data were collected from the Chinese government publications, Chinese language newspapers and magazines, industry associations, local governments' industry bureaus, industry publications, and our in-house databases. Interviews are conducted with Chinese industry experts, university professors, and producers in China. Economic models and quantitative methods are applied in this report to project market demand and industry trends. Metric system is used and values are presented in either Yuan (RMB, current price) and/or US dollars. Our market research reports provide hard-to-find market data and analyses. Today, China has the largest market in the world. Tremendous fast-growing markets for imports and business opportunities for companies around the world. If you want to expand your business or sell your products in China, our research reports provide the insights and projections into Chinese markets necessary for you to do so. Key Topics Covered: I. INTRODUCTION Report Scope and Methodology Executive Summary II. BUSINESS ENVIRONMENT Economic Outlook Key Economic Indicators Industrial Output Population and Labor Foreign Investment Foreign Trade Financial and Tax Regulations Banking System and Regulations Foreign Exchange Taxes, Tariff and Custom Duties III. SLEEP DISORDER TREATMENT DRUGS INDUSTRY ASSESSMENTS Sleep Disorder Treatment Drugs Industry Structure Market Size Market Growth Driver Sleep Disorder Treatment Drugs Sales Volume Major Producer Facility Locations and Sales Volume Market Share of Key Producers Labor Cost Potential Entrants Major Distributors Major Foreign Investments Technology Development IV. SLEEP DISORDER TREATMENT DRUGS PRODUCTION AND DEMAND Overview Sales Volume of Sleep Disorder Treatment Drugs by Region Sleep Disorder Treatment Drugs Sales Volume Western Sleep Disorder Treatment Drugs Sales Volume Barbiturates Phenobarbital Secobarbital Amobarbital Benzodiazepines Midazolam Estazolam Triazolam Others Non-benzodiazepines Zolpidem Zopiclone Zaleplon Others Chinese Traditional Sleep Disorder Treatment Drugs Sales Volume Acanthopanacis Senticosi Gastrodin Chinese Patent Medicines Sleep Disorder Treatment Drugs Imports and Exports Pricing Trends V. SLEEP DISORDER TREATMENT DRUGS MARKET OUTLOOK Sleep Disorder Treatment Drugs Markets Outlook Government Regulations Health Care Insurance Industry Overview Consumer Spending Trends Northeast North Southeast Central Southwest Northwest Demographic Trends Health Care Industry Trends Hospitals and Hospital Beds VI. MARKETING STRATEGIES China Market Entry Overview China's Distribution System Sleep Disorder Treatment Drugs Distribution Channels Transportation and Freight Infrastructure Communications China's Market Entry Export to China Indirect export Direct Export License and Contract Manufacture Assembling in China Contract Manufacturing Trade Permit Investment Equity Joint Venture Contractual Joint Venture Wholly Foreign-Owned Enterprise VII. SLEEP DISORDER TREATMENT DRUGS PRODUCER DIRECTORY Sleep Disorder Treatment Drugs Producer Profiles and Directory A selection of companies mentioned in this report includes Wusuli River Pharmaceutical Group Wandashan Pharmaceutical Factory For more information about this report visit https://www.researchandmarkets.com/r/irmoip About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

26 Jan 2023

·www.businesswire.com

China Sleep Disorder Treatment Drugs Industry Forecasts 2023: Demand to Grow by 5% Annually Through 2032 - ResearchAndMarkets.com

DUBLIN--( BUSINESS WIRE )--The "Sleep Disorder Treatment Drugs Industry Forecasts - China Focus" report has been added to ResearchAndMarkets.com's offering. This study focuses on China's Sleep Disorder Treatment Drugs industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China's society and economy. China is one of the world's major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world's fastest growing market for the consumptions of goods and services. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. Rapid consolidation between medium and large players is anticipated since the Chinese government has been encouraging industry consolidation with an effort to regulate the industry and to improve competitiveness in the world market. Although China has enjoyed the benefits of an expanding market for production and distribution, the industry is suffering from minimal innovation and investment in R&D and new product development. The sector's economies of scale have yet to be achieved. Most domestic manufacturers lack the autonomic intellectual property and financial resources to develop their own brand name products. This new study focuses on industry trends and forecasts with historical data (2012, 2017 and 2022) and long-term forecasts through 2027 and 2032 are presented. The primary and secondary research is done in China in order to access up-to-date government regulations, market information and industry data. Data were collected from the Chinese government publications, Chinese language newspapers and magazines, industry associations, local governments' industry bureaus, industry publications, and our in-house databases. The analyst is one of the leading sources for up-to-date market information and research on the fastest-growing Chinese markets. We have published over 1,500 reports focusing on the Chinese markets, industry forecasts and company profiles. We provide hard-to-find market data and analyses. Our publications are intended to help international marketers identify business opportunities and promote their product sales in the Chinese markets. Key Topics Covered: I. INTRODUCTION Report Scope and Methodology Executive Summary II. BUSINESS ENVIRONMENT Economic Outlook Key Economic Indicators Industrial Output Population and Labor Foreign Investment Foreign Trade Financial and Tax Regulations Banking System and Regulations Foreign Exchange Taxes, Tariff and Custom Duties Market Trends Technology Development Market Development Major Industry Development Regional Development Enterprise Development Labor Market Development III. SLEEP DISORDER TREATMENT DRUGS PRODUCTION AND DEMAND Overview Sales Volume of Sleep Disorder Treatment Drugs by Region Sleep Disorder Treatment Drugs Sales Volume Western Sleep Disorder Treatment Drugs Sales Volume Barbiturates Phenobarbital Secobarbital Amobarbital Benzodiazepines Midazolam Estazolam Triazolam Others Non-benzodiazepines Zolpidem Zopiclone Zaleplon Others Chinese Traditional Sleep Disorder Treatment Drugs Sales Volume Acanthopanacis Senticosi Gastrodin Chinese Patent Medicines Sleep Disorder Treatment Drugs Imports and Exports Pricing Trends For more information about this report visit https://www.researchandmarkets.com/r/njb95-disorder?w=4 About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

100 Deals associated with Amobarbital sodium

External Link

KEGG	Wiki	ATC	Drug Bank
D00555	Amobarbital sodium	N05CA02	DB01351

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Status Epilepticus	Australia	Aspen Pharmacare Australia Pty Ltd.	05 Sep 1991
Sedation	Japan	Nippon Shinyaku Co., Ltd.	20 Feb 1950

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Amobarbital sodium

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation